Compare Abbott Laboratories (ABT) vs Huntington Ingalls Industries Inc (HII) Price & Performance

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

HII trades at $326.80, down 1.21% over the past day, with a bullish technical outlook supported by moving averages and key support at $326. The company reported strong Q2 2026 earnings of $5.27 EPS, beating estimates, with revenue growth of 10.9% year-over-year. Recent contract awards, including a $2.2 billion task order for surveillance and intelligence capabilities, highlight ongoing government demand. Valuation metrics show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

The investment outlook is positive, driven by robust defense contracts and operational improvements, with a consensus price target of $359.67 suggesting 10% upside. Risks include dependence on U.S. military spending and potential political headwinds affecting naval budgets. Analyst sentiment is mixed but leans bullish, with 44% buy ratings. Overall, HII presents a solid opportunity in the defense sector, though investors should monitor contract execution and macroeconomic factors.